Structural basis of specific inhibition of tissue-type plasminogen activator by plasminogen activators inhibitor-1

Thrombosis is a leading cause of death worldwide [1]. Recombinant tissue-type plasminogen activator (tPA) is the FDA-approved thrombolytic drug for ischemic strokes, myocardial infarction and pulmonary embolism. tPA is a multi-domain serine protease of the trypsin-family [2] and catalyses the critic...

Descripción completa

Detalles Bibliográficos
Autores principales: Gong, Lihu, Liu, Min, Zeng, Tu, Shi, Xiaoli, Yuan, Cai, Andreasen, Peter A., Huang, Mingdong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Data Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4731420/
https://www.ncbi.nlm.nih.gov/pubmed/26909366
http://dx.doi.org/10.1016/j.dib.2015.12.050

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4731420/
https://www.ncbi.nlm.nih.gov/pubmed/26909366
http://dx.doi.org/10.1016/j.dib.2015.12.050

Ejemplares similares